By otakuyassine3@gmail.com 
United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $356.68, for a total transaction of $3,566,800.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $919,164.36. The trade was a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Michael Benkowitz also recently made the following trade(s):
- On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $361.95, for a total transaction of $3,619,500.00.
- On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00.
- On Monday, November 11th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The stock was sold at an average price of $407.32, for a total value of $6,109,800.00.
- On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00.
- On Friday, November 1st, Michael Benkowitz sold 14,700 shares of United Therapeutics stock. The shares were sold at an average price of $374.46, for a total value of $5,504,562.00.
United Therapeutics Price Performance
Shares of UTHR opened at $360.22 on Friday. The firm has a 50-day simple moving average of $370.27 and a two-hundred day simple moving average of $349.97. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The stock has a market cap of $16.08 billion, a PE ratio of 15.82, a P/E/G ratio of 1.05 and a beta of 0.55.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the previous year, the company earned $5.38 earnings per share. The firm’s quarterly revenue was up 22.9% compared to the same quarter last year. As a group, sell-side analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. Jefferies Financial Group upped their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. HC Wainwright increased their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. TD Cowen upped their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. LADENBURG THALM/SH SH increased their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Argus boosted their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $370.86.
View Our Latest Stock Report on UTHR
Hedge Funds Weigh In On United Therapeutics
Several hedge funds have recently bought and sold shares of the company. ClariVest Asset Management LLC lifted its position in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares in the last quarter. USA Financial Formulas purchased a new stake in United Therapeutics during the 3rd quarter worth approximately $33,000. Brooklyn Investment Group acquired a new stake in United Therapeutics during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP purchased a new position in United Therapeutics in the 3rd quarter valued at approximately $82,000. Finally, Values First Advisors Inc. purchased a new position in United Therapeutics in the 3rd quarter valued at approximately $90,000. Institutional investors and hedge funds own 94.08% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More
Receive News & Ratings for United Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for United Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.